CD3 invests directly in biotech companies with promising therapeutic programs, complementing its spin-off activities. Backed by €84 million, this provides access to capital at stages where scientific and operational risk are highest and traditional investors are often less active.

Companies gain direct access to an experienced drug discovery team beyond pure funding. This enables hands-on scientific and strategic support throughout development, including guidance on target validation, discovery strategy and positioning for downstream development and partnering.

For biotech teams, this means working with a partner committed to long-term engagement and shared risk, focused on advancing high-potential science into meaningful development opportunities.

Looking for an investor with deep drug discovery expertise?